Literature DB >> 17285578

Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition.

Anne E Cust1, Naomi E Allen, Sabina Rinaldi, Laure Dossus, Christine Friedenreich, Anja Olsen, Anne Tjønneland, Kim Overvad, Françoise Clavel-Chapelon, Marie-Christine Boutron-Ruault, Jakob Linseisen, Jenny Chang-Claude, Heiner Boeing, Mandy Schulz, Vassiliki Benetou, Antonia Trichopoulou, Dimitrios Trichopoulos, Domenico Palli, Franco Berrino, Rosario Tumino, Amalia Mattiello, Paolo Vineis, J Ramón Quirós, Antonio Agudo, Maria-Jose Sánchez, Nerea Larrañaga, Carmen Navarro, Eva Ardanaz, H Bas Bueno-de-Mesquita, Petra H M Peeters, Carla H van Gils, Sheila Bingham, Kay-Tee Khaw, Tim Key, Nadia Slimani, Elio Riboli, Rudolf Kaaks.   

Abstract

We conducted a case-control study nested within the European Prospective Investigation into Cancer and Nutrition, to examine the associations between prediagnostic serum concentrations of C-peptide, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-2, and endometrial cancer risk. Among pre- and post-menopausal women, who were not currently using exogenous hormones, 286 women developed incident endometrial cancer during an average 5.1 years follow-up. Using risk set sampling, 555 matched control subjects were selected. In conditional logistic regression models adjusted for matching factors only, endometrial cancer risk increased with increasing serum levels of C-peptide (relative risks (RR) for the top vs. bottom quartile = 2.13 [95% confidence interval (CI) 1.33-3.41], p(trend) = 0.001, and decreasing serum levels of IGFBP-2 (RR for the top vs. bottom quartile = 0.56 [95% CI 0.35-0.90], p(trend) = 0.03, but was not significantly associated with IGFBP-1 levels (RR for the top vs. bottom quartile = 0.76 [95% CI 0.47-1.21], p(trend) = 0.25). In BMI-adjusted models, only the C-peptide association remained marginally statistically significant (RR for the top vs. bottom quartile = 1.56 [95% CI 0.94-2.57], p(trend) = 0.05 for C-peptide; 0.84 [95% CI 0.50-1.40], p(trend) = 0.74 for IGFBP-2; and 1.08 [95% CI 0.65-1.78], p(trend) = 0.86 for IGFBP-1 levels). These associations were stronger among nonfasting women (< or =< or =6 hr since last meal; 63% of subjects) but were not evident among fasting women, although the interactions were not statistically significant. The C-peptide-risk association was substantially attenuated after adjustment for free estradiol in postmenopausal women (RR for the top vs. bottom quartile = 1.28 [95% CI 0.67-2.45], p(trend) = 0.42. Our results provide modest support to the hypothesis that hyperinsulinaemia is a risk factor for endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17285578     DOI: 10.1002/ijc.22578

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  27 in total

Review 1.  Glycemic index, glycemic load and endometrial cancer risk: results from the Australian National Endometrial Cancer study and an updated systematic review and meta-analysis.

Authors:  Christina M Nagle; Catherine M Olsen; Torukiri I Ibiebele; Amanda B Spurdle; Penelope M Webb
Journal:  Eur J Nutr       Date:  2012-05-22       Impact factor: 5.614

2.  Endometrial Cancer Insulin-Like Growth Factor 1 Receptor (IGF1R) Expression Increases with Body Mass Index and Is Associated with Pathologic Extent and Prognosis.

Authors:  Amy S Joehlin-Price; Julie A Stephens; Jianying Zhang; Floor J Backes; David E Cohn; Adrian A Suarez
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-12-18       Impact factor: 4.254

3.  Analysis of serum metabolic profiles in women with endometrial cancer and controls in a population-based case-control study.

Authors:  Mia M Gaudet; Roni T Falk; Robert D Stevens; Marc J Gunter; James R Bain; Ruth M Pfeiffer; Nancy Potischman; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Montserrat Garcia-Closas; Christopher B Newgard; Mark E Sherman
Journal:  J Clin Endocrinol Metab       Date:  2012-06-22       Impact factor: 5.958

4.  A prospective cohort study of coffee consumption and risk of endometrial cancer over a 26-year follow-up.

Authors:  Youjin Je; Susan E Hankinson; Shelley S Tworoger; Immaculata De Vivo; Edward Giovannucci
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-11-22       Impact factor: 4.254

Review 5.  Understanding obesity and endometrial cancer risk: opportunities for prevention.

Authors:  Rosemarie E Schmandt; David A Iglesias; Ngai Na Co; Karen H Lu
Journal:  Am J Obstet Gynecol       Date:  2011-06-07       Impact factor: 8.661

6.  Metabolic syndrome and risk of endometrial cancer in postmenopausal women: a prospective study.

Authors:  Rhonda S Arthur; Geoffrey C Kabat; Mimi Y Kim; Robert A Wild; Aladdin H Shadyab; Jean Wactawski-Wende; Gloria Y F Ho; Katherine W Reeves; Lewis H Kuller; Juhua Luo; Jennifer Beebe-Dimmer; Michael S Simon; Howard Strickler; Sylvia Wassertheil-Smoller; Thomas E Rohan
Journal:  Cancer Causes Control       Date:  2019-02-20       Impact factor: 2.506

7.  Metabolic syndrome is an independent prognostic factor for endometrial adenocarcinoma.

Authors:  J Ni; T Zhu; L Zhao; F Che; Y Chen; H Shou; A Yu
Journal:  Clin Transl Oncol       Date:  2015-08-11       Impact factor: 3.405

8.  A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer.

Authors:  Marc J Gunter; Donald R Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Joann E Manson; Jixin Li; Tiffany G Harris; Thomas E Rohan; Xiaonan Xue; Gloria Y F Ho; Mark H Einstein; Robert C Kaplan; Robert D Burk; Judith Wylie-Rosett; Michael N Pollak; Garnet Anderson; Barbara V Howard; Howard D Strickler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-04       Impact factor: 4.254

Review 9.  Metabolic syndrome and endometrial cancer: a meta-analysis.

Authors:  Katherine Esposito; Paolo Chiodini; Annalisa Capuano; Giuseppe Bellastella; Maria Ida Maiorino; Dario Giugliano
Journal:  Endocrine       Date:  2013-05-03       Impact factor: 3.633

Review 10.  Insulin resistance and hyperinsulinaemia in the development and progression of cancer.

Authors:  Ian F Godsland
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.